VANGUARD GROUP INC 13D and 13G filings for Coherus Oncology, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2026-03-26 5:12 pm Sale | 2026-03-13 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 0 0.000% | -10,028,893 (Position Closed) | Filing |
| 2026-01-30 3:27 pm Sale | 2025-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 10,028,893 8.290% | -328,519 (-3.17%) | Filing |
| 2024-02-13 5:02 pm Purchase | 2023-12-29 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 10,357,412 9.300% | 4,541,530 (+78.09%) | Filing |
| 2023-02-09 11:15 am Purchase | 2022-12-30 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 5,815,882 7.480% | 1,268,353 (+27.89%) | Filing |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 4,547,529 5.920% | 418,594 (+10.14%) | Filing |